Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 14/20 | 0.78 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.74 |
| ▸ | MTOR | P42345 | 2/20 | 0.74 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535232 | 0.88 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3538224 | 0.86 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL29374897 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL610237 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL30943705 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL30943704 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3537126 | 0.84 | PRKDC (0.78) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL31060675 | 0.84 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3537842 | 0.84 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL31061492 | 0.82 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | PRKDC 92/4885PIK3CA 250/4885MTOR 803/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | PRKDC 212/4885PIK3CA 219/4885MTOR 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.